食道がん治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Esophageal Cancer - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0956
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年3月31日
◆ページ数:1342
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Esophageal Cancer – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Esophageal Cancer – Pipeline Review, H1 2020, provides an overview of the Esophageal Cancer (Oncology) pipeline landscape.

Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Esophageal Cancer – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Esophageal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Esophageal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 11, 69, 81, 5, 34, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 6, 4 and 3 molecules, respectively.

Esophageal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Esophageal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Esophageal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Esophageal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Esophageal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Esophageal Cancer (Oncology)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Esophageal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Esophageal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Introduction
Esophageal Cancer – Overview
Esophageal Cancer – Therapeutics Development
Esophageal Cancer – Therapeutics Assessment
Esophageal Cancer – Companies Involved in Therapeutics Development
Esophageal Cancer – Drug Profiles
Esophageal Cancer – Dormant Projects
Esophageal Cancer – Discontinued Products
Esophageal Cancer – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Esophageal Cancer, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Esophageal Cancer - Pipeline by AbbVie Inc, H1 2020
Esophageal Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2020
Esophageal Cancer - Pipeline by ADC Therapeutics SA, H1 2020
Esophageal Cancer - Pipeline by Advanced Accelerator Applications SA, H1 2020
Esophageal Cancer - Pipeline by Advenchen Laboratories LLC, H1 2020
Esophageal Cancer - Pipeline by Affimed GmbH, H1 2020
Esophageal Cancer - Pipeline by Agios Pharmaceuticals Inc, H1 2020
Esophageal Cancer - Pipeline by Akeso Biopharma Inc, H1 2020
Esophageal Cancer - Pipeline by Alphamab Oncology, H1 2020
Esophageal Cancer - Pipeline by Ambrx Inc, H1 2020
Esophageal Cancer - Pipeline by amcure GmbH, H1 2020
Esophageal Cancer - Pipeline by AMI Onco Theranostics LLC, H1 2020
Esophageal Cancer - Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, H1 2020
Esophageal Cancer - Dormant Projects, H1 2020
Esophageal Cancer - Discontinued Products, H1 2020
Esophageal Cancer - Discontinued Products, H1 2020 (Contd..1), H1 2020

【掲載企業】

AbbVie Inc
Adaptimmune Therapeutics Plc
ADC Therapeutics SA
Advanced Accelerator Applications SA
Advenchen Laboratories LLC
Affimed GmbH
Agios Pharmaceuticals Inc
Akeso Biopharma Inc
Alphamab Oncology
Ambrx Inc
amcure GmbH
AMI Onco Theranostics LLC
Anhui Anke Biotechnology (Group) Co Ltd
Anhui Kedgene Biotechnology Co Ltd
Apexigen Inc
Apollomics Inc
Aprea Therapeutics AB
Ascenta Therapeutics Inc
Ascentage Pharma Group International
Astellas Pharma Inc
AstraZeneca Plc
AVEO Oncology Inc
Bayer AG
BeiGene Ltd
Bicycle Therapeutics Plc
BioMed Valley Discoveries Inc
Biostage Inc
BioStar Pharmaceuticals Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Cantargia AB
Celldex Therapeutics Inc
Cellular Biomedicine Group Inc
Chi Cheung (Shanghai) Biomedical Co Ltd
Chugai Pharmaceutical Co Ltd
Coherent Biopharma
Cotinga Pharmaceuticals Inc
CStone Pharmaceuticals Co Ltd
Curegenix Inc
Cyclacel Pharmaceuticals Inc
Cytlimic Inc
CytomX Therapeutics Inc
DAE HWA Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Delta-Fly Pharma Inc
Dragonboat Biopharmaceutical (Shanghai)Co Ltd
Eisai Co Ltd
Eli Lilly and Co
Evelo Biosciences Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Genmab AS
GlaxoSmithKline Plc
GLG Pharma SA
GlycoNex Inc
Glycotope GmbH
Gossamer Bio Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
Guangzhou Anjie Biomedical Technology Co Ltd
Guangzhou Saliai Stemcell Science and Technology Co Ltd
Hanmi Pharmaceuticals Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
HEC Pharm Co Ltd
Hualan Biological Engineering Inc
Hutchison MediPharma Ltd
Idera Pharmaceuticals Inc
ImmuneSensor Therapeutics Inc
Immunocore Ltd
Immunomedics Inc
ImmunoRestoration LLC
Immvira Co Ltd
Incyte Corp
Innovent Biologics Inc
Inovio Pharmaceuticals Inc
Ipsen SA
Jacobio Pharmaceuticals Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Kitov Pharma Ltd
Kymab Ltd
Leap Therapeutics Inc
LEXEO Therapeutics LLC
LIfT BioSciences Ltd
MaxiVAX SA
Medical Guidance Systems LLC
Merck & Co Inc
Merck KGaA
Mereo Biopharma Group Plc
Moderna Inc
Modra Pharmaceuticals BV
Molecular Templates Inc
New B Innovation Ltd
NGM Biopharmaceuticals Inc
Novartis AG
Novita Pharmaceuticals Inc
OBI Pharma Inc
Omeros Corp
Omnitura Therapeutics Inc
Oncology Venture A/S
Oncolys BioPharma Inc
Onconova Therapeutics Inc
Ono Pharmaceutical Co Ltd
Peptron Inc
Pfizer Inc
Pieris Pharmaceuticals Inc
Prescient Therapeutics Ltd
Puma Biotechnology Inc
Rafael Pharmaceuticals Inc
Rakuten Medical Inc
RAPT Therapeutics Inc
RaQualia Pharma Inc
Replimune Ltd
Revolution Medicines Inc
Rhizen Pharmaceuticals SA
Scancell Holdings Plc
Seattle Genetics Inc
Shanghai Haihe Biopharma Co Ltd
Shanghai Henlius Biotech Inc
Shanghai Junshi Bioscience Co Ltd
Shanghai Keqi Pharmaceutical Technology Co Ltd
Shenyang Dongxing Pharmaceutical Co Ltd
Shenzhen BinDeBio Ltd
Shenzhen Hornetcorn Bio-technology Company Ltd
Shenzhen NeoCura Biotechnology Corp
Shionogi & Co Ltd
Sino Biopharmaceutical Ltd
Sinocelltech Ltd
Soricimed Biopharma Inc
Sorrento Therapeutics Inc
Starpharma Holdings Ltd
Steba Biotech SA
Stemirna Therapeutics Inc
Supratek Pharma Inc
Suzhou Sinovent Pharmaceuticals Co Ltd
Suzhou Stainwei Biotech Inc
Taiho Pharmaceutical Co Ltd
Takara Bio Inc
Takeda Pharmaceutical Co Ltd
Telix Pharmaceuticals Ltd
Tessa Therapeutics Pte Ltd
Themis Bioscience GmbH
TOT Biopharm Co Ltd
Transgene Biotek Ltd
Transgene SA
Turnstone Biologics Inc
Tyg Oncology Ltd
Veana Therapeutics LLC
Viral Gene Inc
Xiangxue Life Sciences
XuanZhu Pharma Co Ltd
Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd
Zymeworks Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[食道がん治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆